WO2002016436A3 - ANTIBODIES TO HUMAN IL-1$g(b) - Google Patents
ANTIBODIES TO HUMAN IL-1$g(b) Download PDFInfo
- Publication number
- WO2002016436A3 WO2002016436A3 PCT/EP2001/009588 EP0109588W WO0216436A3 WO 2002016436 A3 WO2002016436 A3 WO 2002016436A3 EP 0109588 W EP0109588 W EP 0109588W WO 0216436 A3 WO0216436 A3 WO 0216436A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- human
- antibodies
- antibody
- 1βis
- cdrs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
Abstract
Priority Applications (32)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0300806A HU228159B1 (en) | 2000-08-22 | 2001-08-20 | Antibodies to human il-1beta |
US10/362,082 US7446175B2 (en) | 2000-08-22 | 2001-08-20 | Antibodies to human IL-1β |
SI200130844T SI1313769T2 (en) | 2000-08-22 | 2001-08-20 | Antibodies to human il-1 beta |
CA2420231A CA2420231C (en) | 2000-08-22 | 2001-08-20 | Antibodies to human il-1.beta. |
AU2001295490A AU2001295490B2 (en) | 2000-08-22 | 2001-08-20 | Antibodies to human IL-1beta |
DE122009000078C DE122009000078I1 (en) | 2000-08-22 | 2001-08-20 | ANTIBODIES TO IL-1 BETA |
DK01976118.8T DK1313769T4 (en) | 2000-08-22 | 2001-08-20 | Antibodies to human IL-1 beta |
ES01976118T ES2305110T5 (en) | 2000-08-22 | 2001-08-20 | ANTIBODIES AGAINST IL-1 HUMAN BETA. |
SK213-2003A SK288089B6 (en) | 2000-08-22 | 2001-08-20 | IL-1 Beta binding molecule, expression vector, process for production of IL-1 beta binding molecule, use of antibody and pharmaceutical composition |
KR1020037002161A KR100910789B1 (en) | 2000-08-22 | 2001-08-20 | Antibodies to human IL-1? |
EP01976118A EP1313769B2 (en) | 2000-08-22 | 2001-08-20 | Antibodies to human il-1 beta |
NZ524199A NZ524199A (en) | 2000-08-22 | 2001-08-20 | Antibodies to human IL-1beta |
MXPA03001590A MXPA03001590A (en) | 2000-08-22 | 2001-08-20 | ANTIBODIES TO HUMAN IL-1bgr;. |
DE60134148T DE60134148D1 (en) | 2000-08-22 | 2001-08-20 | ANTIBODIES TO IL-1 BETA |
PL360358A PL212480B1 (en) | 2000-08-22 | 2001-08-20 | ANTIBODIES TO HUMAN IL-1β |
AU9549001A AU9549001A (en) | 2000-08-22 | 2001-08-20 | Antibodies to human IL-1beta |
BR0113420-5A BR0113420A (en) | 2000-08-22 | 2001-08-20 | Antibodies to human il-1beta |
IL15446501A IL154465A0 (en) | 2000-08-22 | 2001-08-20 | ANTIBODIES TO HUMAN IL-1beta |
JP2002521531A JP4271936B2 (en) | 2000-08-22 | 2001-08-20 | Antibody against human IL-1β |
IL154465A IL154465A (en) | 2000-08-22 | 2003-02-13 | Il-1beta binding molecules and use thereof in the preparation of pharmaceutical compositions and medicaments |
NO20030827A NO332609B1 (en) | 2000-08-22 | 2003-02-21 | IL-1 <beta> -binding molecule and uses thereof, expression vector, method of preparation and pharmaceutical preparation |
HK04103018.8A HK1061403A1 (en) | 2000-08-22 | 2004-04-29 | ANTIBODIES TO HUMAN IL-1ß |
CY20081100840T CY1108779T1 (en) | 2000-08-22 | 2008-08-11 | ANTIBODIES TO HUMAN IL-1 BETA |
US12/238,502 US7993878B2 (en) | 2000-08-22 | 2008-09-26 | Antibodies to human IL-1β |
NL300427C NL300427I2 (en) | 2000-08-22 | 2009-11-24 | Antibodoes to human IL-1 beta |
LU91624C LU91624I2 (en) | 2000-08-22 | 2009-11-25 | Canakinumab and its pharmaceutically acceptable derivatives (ILARIS®) |
BE2009C057C BE2009C057I2 (en) | 2000-08-22 | 2009-11-30 | |
FR09C0062C FR09C0062I2 (en) | 2000-08-22 | 2009-12-03 | HUMAN IL-1 BETA ANTIBODIES |
CY2009019C CY2009019I2 (en) | 2000-08-22 | 2009-12-09 | ANTIBODIES TO HUMAN IL-1 BETA |
US13/171,631 US8273350B2 (en) | 2000-08-22 | 2011-06-29 | Antibodies to human IL-1β |
NO2012018C NO2012018I1 (en) | 2000-08-22 | 2012-11-21 | Canakinumab or direct equivalents thereof |
NO2017052C NO2017052I2 (en) | 2000-08-22 | 2017-10-11 | Canakinumab - prolonged SPC |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0020685.4A GB0020685D0 (en) | 2000-08-22 | 2000-08-22 | Organic compounds |
GB0020685.4 | 2000-08-22 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10362082 A-371-Of-International | 2001-08-20 | ||
US12/238,502 Continuation US7993878B2 (en) | 2000-08-22 | 2008-09-26 | Antibodies to human IL-1β |
US12/238,502 Division US7993878B2 (en) | 2000-08-22 | 2008-09-26 | Antibodies to human IL-1β |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002016436A2 WO2002016436A2 (en) | 2002-02-28 |
WO2002016436A3 true WO2002016436A3 (en) | 2002-06-20 |
Family
ID=9898090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/009588 WO2002016436A2 (en) | 2000-08-22 | 2001-08-20 | ANTIBODIES TO HUMAN IL-1$g(b) |
Country Status (37)
Country | Link |
---|---|
US (3) | US7446175B2 (en) |
EP (1) | EP1313769B2 (en) |
JP (2) | JP4271936B2 (en) |
KR (2) | KR20080056316A (en) |
CN (1) | CN100547003C (en) |
AR (1) | AR035581A1 (en) |
AT (1) | ATE396206T1 (en) |
AU (2) | AU9549001A (en) |
BE (1) | BE2009C057I2 (en) |
BR (1) | BR0113420A (en) |
CA (1) | CA2420231C (en) |
CY (2) | CY1108779T1 (en) |
CZ (1) | CZ304470B6 (en) |
DE (2) | DE122009000078I1 (en) |
DK (1) | DK1313769T4 (en) |
EC (1) | ECSP034490A (en) |
ES (1) | ES2305110T5 (en) |
FR (1) | FR09C0062I2 (en) |
GB (1) | GB0020685D0 (en) |
HK (1) | HK1061403A1 (en) |
HU (2) | HU228159B1 (en) |
IL (2) | IL154465A0 (en) |
LU (1) | LU91624I2 (en) |
MX (1) | MXPA03001590A (en) |
MY (1) | MY130248A (en) |
NL (1) | NL300427I2 (en) |
NO (3) | NO332609B1 (en) |
NZ (2) | NZ534269A (en) |
PE (1) | PE20020319A1 (en) |
PL (1) | PL212480B1 (en) |
PT (1) | PT1313769E (en) |
RU (1) | RU2286351C2 (en) |
SI (1) | SI1313769T2 (en) |
SK (1) | SK288089B6 (en) |
TW (1) | TWI321568B (en) |
WO (1) | WO2002016436A2 (en) |
ZA (1) | ZA200301275B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8465744B2 (en) | 2003-02-13 | 2013-06-18 | Ucb Pharma S.A. | Method of treating inflammation by administering human IL-1B antibodies |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1339426A4 (en) * | 2000-11-08 | 2004-06-30 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to trail receptors |
ES2449578T3 (en) | 2002-09-06 | 2014-03-20 | Amgen Inc. | Therapeutic human anti-IL-1R1 monoclonal antibody |
US7101978B2 (en) * | 2003-01-08 | 2006-09-05 | Applied Molecular Evolution | TNF-α binding molecules |
AU2004207741B2 (en) * | 2003-01-24 | 2011-02-10 | Applied Molecular Evolution, Inc | Human IL-1 beta antagonists |
WO2004100987A2 (en) * | 2003-05-06 | 2004-11-25 | Regeneron Pharmaceuticals, Inc. | Methods of using il-1 antagonists to treat neointimal hyperplasia |
NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
JP4989456B2 (en) * | 2004-02-26 | 2012-08-01 | ベイラー リサーチ インスティテュート | Compositions and methods for systemic treatment of arthritis |
AU2012213934B9 (en) * | 2005-01-26 | 2013-07-25 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
WO2006081139A2 (en) * | 2005-01-26 | 2006-08-03 | Abgenix, Inc. | Antibodies against interleukin-1 beta |
GB0509512D0 (en) * | 2005-05-10 | 2005-06-15 | Novartis Ag | Organic compounds |
EP2322552B1 (en) | 2005-06-21 | 2016-02-10 | Xoma (Us) Llc | IL-1beta binding antibodies and fragments thereof |
JP2009511545A (en) * | 2005-10-14 | 2009-03-19 | ノボ・ノルデイスク・エー/エス | Treatment of diabetes using IL-1 inhibitors |
KR101749388B1 (en) * | 2005-10-26 | 2017-06-20 | 노파르티스 아게 | Novel use of il-1beta compounds |
WO2007120828A1 (en) * | 2006-04-14 | 2007-10-25 | Novartis Ag | Use of il-i antibodies for treating ophthalmic disorders |
CN103405768A (en) | 2006-12-20 | 2013-11-27 | 爱克索马技术有限公司 | Methods for the treatment of IL-1[beta] related diseases |
CL2008001071A1 (en) * | 2007-04-17 | 2009-05-22 | Smithkline Beecham Corp | Method to obtain penta-specific antibody against human il-8 / cxcl8, gro-alpha / cxcl1, gro-beta / cxcl2), gro-gamma / cxcl3 and ena-78 / cxcl5; penta-specific antibody; production process of the same; vector, hybridoma or cella that comprises it; pharmaceutical composition; use to treat copd, other diseases. |
BRPI0812040A2 (en) * | 2007-05-29 | 2014-10-21 | Novartis Ag | INDICATIONS FOR ANTI-IL-I-BETA THERAPY |
EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
EP2391650B1 (en) | 2007-12-20 | 2014-10-15 | Xoma (Us) Llc | Methods for the treatment of gout |
KR20110014607A (en) | 2008-04-29 | 2011-02-11 | 아보트 러보러터리즈 | Dual variable domain immunoglobulins and uses thereof |
TW201008580A (en) | 2008-06-03 | 2010-03-01 | Abbott Lab | Dual variable domain immunoglobulin and uses thereof |
BRPI0913366A8 (en) * | 2008-06-03 | 2017-07-11 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND THEIR USES |
US20110189172A1 (en) * | 2008-06-06 | 2011-08-04 | Xoma Technology, Ltd. | Methods for the treatment of rheumatoid arthritis |
US8822645B2 (en) | 2008-07-08 | 2014-09-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
CA2735940A1 (en) | 2008-09-05 | 2010-03-11 | Xoma Technology Ltd. | Methods for treating or preventing il-1.beta. related diseases |
US20100150864A1 (en) * | 2008-10-20 | 2010-06-17 | Abbott Laboratories, Inc. | Antibodies that bind to il-18 and methods of purifying the same |
US8298533B2 (en) * | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
US20130122008A1 (en) * | 2009-05-06 | 2013-05-16 | Novartis Ag | Anti-IL 1- ß Antibody Combination Therapy |
US8389474B1 (en) * | 2009-07-14 | 2013-03-05 | Alan Anson Wanderer | Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion |
WO2011028811A2 (en) * | 2009-09-01 | 2011-03-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
CN102666875A (en) | 2009-10-15 | 2012-09-12 | 雅培制药有限公司 | Dual variable domain immunoglobulins and uses thereof |
KR101860175B1 (en) | 2009-10-26 | 2018-05-21 | 에프. 호프만-라 로슈 아게 | Method for the production of a glycosylated immunoglobulin |
UY32979A (en) | 2009-10-28 | 2011-02-28 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
EA201201526A1 (en) * | 2010-05-07 | 2013-06-28 | Ксома Текнолоджи Лтд. | METHODS OF TREATING CONDITIONS ASSOCIATED WITH IL-1B |
CN103298834A (en) | 2010-08-03 | 2013-09-11 | Abbvie公司 | Dual variable domain immunoglobulins and uses thereof |
US9046513B2 (en) | 2010-08-26 | 2015-06-02 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
CN103492416A (en) | 2011-04-15 | 2014-01-01 | 默克专利股份公司 | Anti- IL-1R1 inhibitors for use in cancer |
EP2731971A1 (en) | 2011-07-12 | 2014-05-21 | Universität Zürich | MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE |
DE102011083595A1 (en) | 2011-09-28 | 2013-03-28 | Bayer Pharma AG | Inhibition of the effect of interleukin 1 beta for the treatment of endometriosis |
AU2012316083A1 (en) | 2011-09-30 | 2014-04-17 | Novartis Ag | Use of IL-1 beta binding antibodies |
AP2014007680A0 (en) | 2011-12-02 | 2014-06-30 | Novartis Ag | Anti-1L-beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease |
CA2855840C (en) | 2011-12-14 | 2023-08-29 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
US20150010544A1 (en) | 2011-12-16 | 2015-01-08 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
US20150017157A1 (en) | 2011-12-19 | 2015-01-15 | Xoma (Us) Llc | Methods for treating acne |
JP2015508994A (en) | 2011-12-30 | 2015-03-26 | アッヴィ・インコーポレイテッド | Dual variable domain immunoglobulins against IL-13 and / or IL-17 |
JP6383665B2 (en) | 2012-02-13 | 2018-08-29 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | IL-1β neutralizing human monoclonal antibody |
CN103588878A (en) * | 2012-08-15 | 2014-02-19 | 江苏泰康生物医药有限公司 | Humanized anti-human-interleukin-1[belta] monoclonal antibody, preparation thereof and applications thereof |
RU2636043C2 (en) | 2012-11-01 | 2017-11-17 | Эббви Инк. | Anti-vegf/dll4-immunoglobulins with double variable domains and their application |
BR112015009892B1 (en) | 2012-11-05 | 2022-12-27 | Delenex Therapeutics Ag | ANTIBODY AGAINST IL-1 BETA, ITS PRODUCTION METHOD AND USE, ISOLATED NUCLEIC ACID SEQUENCE, VECTOR, COSMETIC, DIAGNOSTIC OR PHARMACEUTICAL COMPOSITION, AND KIT |
US10000565B2 (en) | 2012-11-16 | 2018-06-19 | Novartis Ag | Use of IL-1 β binding antibodies for treating peripheral arterial disease |
WO2014095808A1 (en) | 2012-12-17 | 2014-06-26 | Delenex Therapeutics Ag | Antibodies against il-1 beta |
CA2891686A1 (en) | 2012-12-18 | 2014-06-26 | Novartis Ag | Compositions and methods that utilize a peptide tag that binds to hyaluronan |
AU2014227732A1 (en) | 2013-03-15 | 2015-09-17 | Abbvie Inc. | Dual specific binding proteins directed against IL-1 beta and IL-17 |
WO2015083120A1 (en) | 2013-12-04 | 2015-06-11 | Novartis Ag | USE OF IL-1β BINDING ANTIBODIES |
US20170290876A1 (en) | 2014-06-25 | 2017-10-12 | Novartis Ag | Compositions and methods for long acting proteins |
EP3160991A2 (en) | 2014-06-25 | 2017-05-03 | Novartis AG | Compositions and methods for long acting proteins |
WO2016008851A1 (en) * | 2014-07-14 | 2016-01-21 | Boehringer Ingelheim International Gmbh | Anti-il-1b antibodies |
MA41044A (en) | 2014-10-08 | 2017-08-15 | Novartis Ag | COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT |
SG11201702401RA (en) | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
CA2963606A1 (en) | 2014-11-10 | 2016-05-19 | F.Hoffmann-La Roche Ag | Anti-ang2 antibodies and methods of use |
JP2017537896A (en) | 2014-11-10 | 2017-12-21 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Bispecific antibodies and methods for use in ophthalmology |
WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
CA2988055A1 (en) | 2015-06-04 | 2016-12-08 | Novartis Ag | Use of il-1 beta binding antibodies to treat peripheral arterial disease |
TW201710286A (en) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | Binding proteins against VEGF, PDGF, and/or their receptors |
EP3964528A1 (en) | 2015-07-29 | 2022-03-09 | Novartis AG | Combination therapies comprising antibody molecules to lag-3 |
US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
CN108495651A (en) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | The antibody molecule and application thereof of anti-PD-1 |
WO2017153936A1 (en) | 2016-03-10 | 2017-09-14 | Novartis Ag | Chemically modified messenger rna's |
AU2017298656A1 (en) | 2016-07-21 | 2019-02-07 | Novartis Ag | Use of the IL-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis |
EP3551034A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
US20200315540A1 (en) | 2016-12-14 | 2020-10-08 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor |
UY37758A (en) | 2017-06-12 | 2019-01-31 | Novartis Ag | METHOD OF MANUFACTURING OF BIESPECTIFIC ANTIBODIES, BISPECTIFIC ANTIBODIES AND THERAPEUTIC USE OF SUCH ANTIBODIES |
WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
WO2018234879A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
EP3710475A1 (en) | 2017-08-25 | 2020-09-23 | Novartis AG | Use of canakinumab |
CA3075711A1 (en) * | 2017-09-13 | 2019-03-21 | Novartis Ag | Use of il-1 b binding antibodies for the treatment of alcoholic hepatitis |
JP2021503478A (en) | 2017-11-16 | 2021-02-12 | ノバルティス アーゲー | Combination treatment |
EP3790576A1 (en) | 2018-05-09 | 2021-03-17 | Novartis Ag | Use of canakinumab |
CR20200571A (en) | 2018-06-01 | 2021-01-18 | Novartis Ag | Binding molecules against bcma and uses thereof |
AR116109A1 (en) | 2018-07-10 | 2021-03-31 | Novartis Ag | DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME |
GB2575853A (en) * | 2018-07-25 | 2020-01-29 | Robert Wotherspoon Hugh | IL-1ß binding antibody |
CN110818793A (en) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | Antibodies against IL-1 β, pharmaceutical compositions thereof and uses thereof |
WO2020039401A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | Treatment comprising il-1βeta binding antibodies and combinations thereof |
JP7256266B2 (en) * | 2018-11-07 | 2023-04-11 | 沢達生物医薬有限公司 | ANTIBODY BINDING HUMAN IL-1β, PREPARATION METHOD AND USE THEREOF |
WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
WO2020128613A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1beta binding antibodies |
GB201901187D0 (en) | 2019-01-29 | 2019-03-20 | Autolus Ltd | Treatment of neurotoxicity and/or cytokine release syndrome |
WO2020165834A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CA3124935A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
EP4073115A1 (en) | 2019-12-09 | 2022-10-19 | Novartis AG | Anti-interleukin 1 beta antibodies for treatment of sickle cell disease |
EP3870261B1 (en) | 2019-12-13 | 2024-01-31 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
US20230056470A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
TWI793503B (en) | 2020-01-20 | 2023-02-21 | 美商美國禮來大藥廠 | ANTI-IL-1β ANTIBODIES |
WO2021257539A1 (en) * | 2020-06-16 | 2021-12-23 | Academia Sinica | ANTIBODIES TO INTERLEUKIN-1β AND USES THEREOF |
JP2023531676A (en) | 2020-06-23 | 2023-07-25 | ノバルティス アーゲー | Dosing Regimens Containing 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives |
WO2022023907A1 (en) | 2020-07-31 | 2022-02-03 | Novartis Ag | Methods of selecting and treating patients at elevated risk of major adverse cardiac events |
WO2022097060A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
WO2022167916A1 (en) | 2021-02-03 | 2022-08-11 | Novartis Ag | Use of il-1b binding antibodies for treating neuroinflammatory disorders |
TW202304979A (en) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
AR125874A1 (en) | 2021-05-18 | 2023-08-23 | Novartis Ag | COMBINATION THERAPIES |
CN117355323A (en) | 2021-05-24 | 2024-01-05 | 诺华股份有限公司 | Methods for treating osteoarthritis |
TW202306989A (en) | 2021-06-22 | 2023-02-16 | 瑞士商諾華公司 | Bispecific antibodies for use in treatment of hidradenitis suppurativa |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US534858A (en) * | 1895-02-26 | Workman s time-recorder | ||
EP0267611A2 (en) * | 1986-11-13 | 1988-05-18 | Otsuka Pharmaceutical Co., Ltd. | Antibody against interleukin-1 |
US4935343A (en) * | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
WO1995001997A1 (en) * | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1172789A (en) | 1980-09-25 | 1984-08-14 | Hideo Kasahara | POLYMERIC MATERIAL COMPRISING A POLYAMIDE BONDED TO A COPOLYMER CONTAINING AN IMIDE OF AN .alpha.,.beta. UNSATURATED CARBOXYLIC ACID |
US4772685A (en) | 1985-10-02 | 1988-09-20 | Merck & Co., Inc. | Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
DE3785186T2 (en) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | BINDING MOLECULE WITH SINGLE POLYPEPTIDE CHAIN. |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
EP0364778B1 (en) | 1988-10-01 | 1996-03-13 | Otsuka Pharmaceutical Co., Ltd. | Antibody against interleukin-1beta |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
FR2640146B1 (en) | 1988-12-08 | 1993-12-24 | Commissariat A Energie Atomique | ANTI-INTERLEUKIN MONOCLONAL ANTIBODIES 1 (ALPHA) AND 1 (BETA), THEIR PRODUCTION METHOD AND APPLICATIONS OF SAID ANTIBODIES TO DETECTION OF INTERLEUKINS 1 (ALPHA) AND 1 (BETA) AND THERAPEUTICS |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
CA2018248A1 (en) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
ATE356869T1 (en) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | FORMATION OF XENOGENE ANTIBODIES |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
ES2108048T3 (en) | 1990-08-29 | 1997-12-16 | Genpharm Int | PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES. |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
JP3714683B2 (en) | 1992-07-30 | 2005-11-09 | 生化学工業株式会社 | Anti-rheumatic agent |
US5429614A (en) | 1993-06-30 | 1995-07-04 | Baxter International Inc. | Drug delivery system |
US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
GB0001448D0 (en) | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
-
2000
- 2000-08-22 GB GBGB0020685.4A patent/GB0020685D0/en not_active Ceased
-
2001
- 2001-08-16 PE PE2001000817A patent/PE20020319A1/en not_active Application Discontinuation
- 2001-08-17 AR ARP010103946A patent/AR035581A1/en active IP Right Grant
- 2001-08-20 AU AU9549001A patent/AU9549001A/en active Pending
- 2001-08-20 AU AU2001295490A patent/AU2001295490B2/en active Active
- 2001-08-20 CZ CZ2003-505A patent/CZ304470B6/en unknown
- 2001-08-20 NZ NZ534269A patent/NZ534269A/en not_active IP Right Cessation
- 2001-08-20 US US10/362,082 patent/US7446175B2/en not_active Expired - Lifetime
- 2001-08-20 PT PT01976118T patent/PT1313769E/en unknown
- 2001-08-20 HU HU0300806A patent/HU228159B1/en active Protection Beyond IP Right Term
- 2001-08-20 PL PL360358A patent/PL212480B1/en unknown
- 2001-08-20 AT AT01976118T patent/ATE396206T1/en active
- 2001-08-20 CA CA2420231A patent/CA2420231C/en not_active Expired - Lifetime
- 2001-08-20 IL IL15446501A patent/IL154465A0/en unknown
- 2001-08-20 SK SK213-2003A patent/SK288089B6/en not_active IP Right Cessation
- 2001-08-20 KR KR1020087012282A patent/KR20080056316A/en not_active Application Discontinuation
- 2001-08-20 WO PCT/EP2001/009588 patent/WO2002016436A2/en active IP Right Grant
- 2001-08-20 DE DE122009000078C patent/DE122009000078I1/en active Pending
- 2001-08-20 NZ NZ524199A patent/NZ524199A/en not_active IP Right Cessation
- 2001-08-20 JP JP2002521531A patent/JP4271936B2/en not_active Expired - Lifetime
- 2001-08-20 RU RU2003107564/13A patent/RU2286351C2/en active Protection Beyond IP Right Term
- 2001-08-20 CN CNB018145140A patent/CN100547003C/en not_active Expired - Lifetime
- 2001-08-20 MX MXPA03001590A patent/MXPA03001590A/en active IP Right Grant
- 2001-08-20 KR KR1020037002161A patent/KR100910789B1/en active IP Right Grant
- 2001-08-20 SI SI200130844T patent/SI1313769T2/en unknown
- 2001-08-20 EP EP01976118A patent/EP1313769B2/en not_active Expired - Lifetime
- 2001-08-20 DE DE60134148T patent/DE60134148D1/en not_active Expired - Lifetime
- 2001-08-20 BR BR0113420-5A patent/BR0113420A/en not_active IP Right Cessation
- 2001-08-20 ES ES01976118T patent/ES2305110T5/en not_active Expired - Lifetime
- 2001-08-20 DK DK01976118.8T patent/DK1313769T4/en active
- 2001-08-21 MY MYPI20013927A patent/MY130248A/en unknown
- 2001-08-22 TW TW090120626A patent/TWI321568B/en not_active IP Right Cessation
-
2003
- 2003-02-13 IL IL154465A patent/IL154465A/en active Protection Beyond IP Right Term
- 2003-02-17 ZA ZA200301275A patent/ZA200301275B/en unknown
- 2003-02-19 EC EC2003004490A patent/ECSP034490A/en unknown
- 2003-02-21 NO NO20030827A patent/NO332609B1/en not_active IP Right Cessation
-
2004
- 2004-04-29 HK HK04103018.8A patent/HK1061403A1/en not_active IP Right Cessation
-
2008
- 2008-08-01 JP JP2008199799A patent/JP2008295456A/en active Pending
- 2008-08-11 CY CY20081100840T patent/CY1108779T1/en unknown
- 2008-09-26 US US12/238,502 patent/US7993878B2/en not_active Expired - Fee Related
-
2009
- 2009-11-24 NL NL300427C patent/NL300427I2/en unknown
- 2009-11-25 LU LU91624C patent/LU91624I2/en unknown
- 2009-11-30 BE BE2009C057C patent/BE2009C057I2/fr unknown
- 2009-12-03 FR FR09C0062C patent/FR09C0062I2/en active Active
- 2009-12-09 CY CY2009019C patent/CY2009019I2/en unknown
-
2011
- 2011-06-29 US US13/171,631 patent/US8273350B2/en not_active Expired - Lifetime
-
2012
- 2012-11-21 NO NO2012018C patent/NO2012018I1/en unknown
-
2013
- 2013-04-26 HU HUS1300015C patent/HUS1300015I1/en unknown
-
2017
- 2017-10-11 NO NO2017052C patent/NO2017052I2/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US534858A (en) * | 1895-02-26 | Workman s time-recorder | ||
US4935343A (en) * | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
EP0267611A2 (en) * | 1986-11-13 | 1988-05-18 | Otsuka Pharmaceutical Co., Ltd. | Antibody against interleukin-1 |
WO1995001997A1 (en) * | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
Non-Patent Citations (1)
Title |
---|
JACKSON J R ET AL: "IN VITRO ANTIBODY MUTARATION IMPROVEMENT OF A HIGH AFFINITY, NEUTRALIZING ANTIBODY AGAINST IL-1BETA", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 154, no. 7, 1 April 1995 (1995-04-01), pages 3310 - 3319, XP000941315, ISSN: 0022-1767 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8465744B2 (en) | 2003-02-13 | 2013-06-18 | Ucb Pharma S.A. | Method of treating inflammation by administering human IL-1B antibodies |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002016436A3 (en) | ANTIBODIES TO HUMAN IL-1$g(b) | |
WO2001053353A3 (en) | Recombinant antibodies to human interkleukin-1 beta | |
WO2003030833A3 (en) | Angiopoietin-2 specific binding agents | |
IL195085A0 (en) | Antibody molecules having specifity for human tnf ?? compounds and composition comprising them, dna sequence encoding heavy and light chain of said antibody and process for the production of said antibody | |
TNSN07034A1 (en) | Il - 17 antagonistic antibodies | |
EP2221317A3 (en) | PEGylated single domain antibodies (dAb) | |
WO2002096948A3 (en) | Engineered tetravalent antibodies and methods of use | |
EP4218801A3 (en) | Antibody modification method for purifying bispecific antibody | |
EP3056511A3 (en) | Il-1beta binding antibodies and fragments thereof | |
DK2314629T3 (en) | Recombinant preparation of mixtures of antibodies | |
WO2005047314A3 (en) | Fgf-beta binding and supported peptides | |
WO2006068975A3 (en) | Binding proteins specific for human matriptase | |
WO2004092215A3 (en) | Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2 | |
WO2005052000A3 (en) | Anti-il-20 antibodies and binding partners and methods of using in inflammation | |
EA200700876A1 (en) | AGENTS SPECIFICALLY BINDING ANGIOPOETIN-2 | |
WO2004067568A3 (en) | Human il-1 beta antagonists | |
WO2004093803A3 (en) | Photochemotherapeutic compounds for use in treatment of pin1-associated states | |
WO2002072826A3 (en) | Neurotrophic factors | |
HK1071898A1 (en) | Recombinant antibodies, and compositions and methods for making and using the same | |
IL169804A (en) | 254p1d6b proteins, nucleic acids encoding the same, processes for producing the same, antibodies binding thereto and uses thereof | |
WO2001055178A3 (en) | Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer | |
WO2005047328A3 (en) | Antibodies against secretoryleukocyte protease inhibitor | |
WO2001096373A3 (en) | Fluorescent timer proteins and methods for their use | |
WO2005000896A3 (en) | Polypeptides that bind an anti-tissue factor antibody and uses thereof | |
WO2003038440A3 (en) | Chemokine binding molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001976118 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 154465 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037002161 Country of ref document: KR Ref document number: 524199 Country of ref document: NZ Ref document number: 276/CHENP/2003 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003/01275 Country of ref document: ZA Ref document number: 200301275 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001295490 Country of ref document: AU Ref document number: 2420231 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2003-500051 Country of ref document: PH Ref document number: 2002521531 Country of ref document: JP Ref document number: 2132003 Country of ref document: SK Ref document number: PV2003-505 Country of ref document: CZ Ref document number: 03014530 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018145140 Country of ref document: CN Ref document number: PA/a/2003/001590 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200300238 Country of ref document: VN |
|
ENP | Entry into the national phase |
Ref document number: 2003107564 Country of ref document: RU Kind code of ref document: A Ref country code: RU Ref document number: RU A |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037002161 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2003-505 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 2001976118 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10362082 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 524199 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 524199 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001295490 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001976118 Country of ref document: EP |